Evidence map›Paper›PMID 39905383›Full record

ArticleBMC musculoskeletal disorders2025

Exploring the potential cost-effectiveness and societal burden implications of screening for fracture risk in a UK general radiography setting.

E Söreskog, B Lopez, T Bean, P Lewis, N Ashley, J Da Palma Lopes, R Meertens, A Ratcliffe

Abstract read
In one paragraph

Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Opportunistic assessment of osteoporosis using hip and pelvic X-rays with OsteoSight™: validation of an AI-based tool in a US population.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

E SöreskogMacanda AB, Stockholm, Sweden.
B LopezIbex Innovations Ltd, Sedgefield, UK. b.lopez@ibexinnovations.co.uk.
T BeanRoyal Cornwall Hospital, Truro, UK.
P LewisRoyal Cornwall Hospital, Truro, UK.
N AshleyRoyal Cornwall Hospital, Truro, UK.
J Da Palma LopesRoyal Cornwall Hospital, Truro, UK.
R MeertensUniversity of Exeter, Exeter, UK.
A RatcliffeIbex Innovations Ltd, Sedgefield, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFragility fractures lead to considerable societal costs and individual suffering. Despite the availability of cost-effective treatments for high-risk patients, a significant treatment gap exists, with many high-risk individuals remaining unidentified and untreated. The aim of this study was to explore the potential cost-effectiveness and societal impact of opportunistic screening for fracture risk with IBEX Bone Health (BH), a software solution that provides bone mineral density from wrist radiographs, in a UK general radiography setting.

methodsThe study used a health economic model that compared the health outcomes and costs of screening with IBEX BH versus usual care for men and women aged 50 and older who had a forearm radiograph for any reason. The model incorporated data on fracture incidence, fracture risk reduction, mortality, quality of life, and fracture and treatment costs from published sources and Royal Cornwall Hospitals NHS Trust. Costs and health outcomes in terms of quality-adjusted life years (QALYs) were simulated over the remaining lifetime of patients. The analysis took the perspective of the National Health Service (NHS) and Personal Social Services in the UK.

resultsThe results showed that screening with IBEX BH was associated with a gain of 0.013 QALYs and a cost saving of £109 per patient compared with usual care, making it a dominant (cost-saving) strategy. Sensitivity analyses confirmed the robustness of the results under various assumptions. Widespread adoption of IBEX BH in the NHS was estimated to save 8,066 QALYs and £65,930,555 in healthcare costs over the lifetime of patients visiting hospitals for wrist radiographs each year.

conclusionsIBEX BH could be a cost-effective tool for early identification and prevention of fragility fractures in the UK, addressing the current challenges of low provision and access to fracture risk assessment and treatment.

Indexed as

Cost of IllnessFractures, BoneHealth Care CostsMass ScreeningOsteoporotic FracturesAgedBone DensityCost-Benefit AnalysisFemaleHumansMaleMiddle AgedModels, EconomicQuality-Adjusted Life YearsRadiographyRisk AssessmentBone HealthCost-effectivenessEconomic evaluationOsteoporosisScreening

Identifiers

PMID39905383
PMCPMC11792445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.